#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0178] According to a first alternative, the nucleic acid of the inventive polymeric carrier cargo complex may encode a polyclonal antibody.
1-1	0-1	[	_	_	
1-2	1-5	0178	_	_	
1-3	5-6	]	_	_	
1-4	7-16	According	_	_	
1-5	17-19	to	_	_	
1-6	20-21	a	_	_	
1-7	22-27	first	_	_	
1-8	28-39	alternative	_	_	
1-9	39-40	,	_	_	
1-10	41-44	the	_	_	
1-11	45-52	nucleic	_	_	
1-12	53-57	acid	_	_	
1-13	58-60	of	_	_	
1-14	61-64	the	_	_	
1-15	65-74	inventive	_	_	
1-16	75-84	polymeric	_	_	
1-17	85-92	carrier	_	_	
1-18	93-98	cargo	_	_	
1-19	99-106	complex	_	_	
1-20	107-110	may	_	_	
1-21	111-117	encode	_	_	
1-22	118-119	a	_	_	
1-23	120-130	polyclonal	_	_	
1-24	131-139	antibody	_	_	
1-25	139-140	.	_	_	

#Text=In this context, the term, "polyclonal antibody" typically means mixtures of antibodies directed to specific antigens or immunogens or epitopes of a protein which were generated by immunization of a host organism, such as a mammal, e.g. including goat, cattle, swine, dog, cat, donkey, monkey, ape, a rodent such as a mouse, hamster and rabbit.
2-1	141-143	In	_	_	
2-2	144-148	this	_	_	
2-3	149-156	context	_	_	
2-4	156-157	,	_	_	
2-5	158-161	the	_	_	
2-6	162-166	term	_	_	
2-7	166-167	,	_	_	
2-8	168-169	"	_	_	
2-9	169-179	polyclonal	_	_	
2-10	180-188	antibody	_	_	
2-11	188-189	"	_	_	
2-12	190-199	typically	_	_	
2-13	200-205	means	_	_	
2-14	206-214	mixtures	_	_	
2-15	215-217	of	_	_	
2-16	218-228	antibodies	_	_	
2-17	229-237	directed	_	_	
2-18	238-240	to	_	_	
2-19	241-249	specific	_	_	
2-20	250-258	antigens	_	_	
2-21	259-261	or	_	_	
2-22	262-272	immunogens	_	_	
2-23	273-275	or	_	_	
2-24	276-284	epitopes	_	_	
2-25	285-287	of	_	_	
2-26	288-289	a	_	_	
2-27	290-297	protein	_	_	
2-28	298-303	which	_	_	
2-29	304-308	were	_	_	
2-30	309-318	generated	_	_	
2-31	319-321	by	_	_	
2-32	322-334	immunization	_	_	
2-33	335-337	of	_	_	
2-34	338-339	a	_	_	
2-35	340-344	host	_	_	
2-36	345-353	organism	_	_	
2-37	353-354	,	_	_	
2-38	355-359	such	_	_	
2-39	360-362	as	_	_	
2-40	363-364	a	_	_	
2-41	365-371	mammal	_	_	
2-42	371-372	,	_	_	
2-43	373-376	e.g	_	_	
2-44	376-377	.	_	_	
2-45	378-387	including	_	_	
2-46	388-392	goat	_	_	
2-47	392-393	,	_	_	
2-48	394-400	cattle	_	_	
2-49	400-401	,	_	_	
2-50	402-407	swine	_	_	
2-51	407-408	,	_	_	
2-52	409-412	dog	_	_	
2-53	412-413	,	_	_	
2-54	414-417	cat	_	_	
2-55	417-418	,	_	_	
2-56	419-425	donkey	_	_	
2-57	425-426	,	_	_	
2-58	427-433	monkey	_	_	
2-59	433-434	,	_	_	
2-60	435-438	ape	_	_	
2-61	438-439	,	_	_	
2-62	440-441	a	_	_	
2-63	442-448	rodent	_	_	
2-64	449-453	such	_	_	
2-65	454-456	as	_	_	
2-66	457-458	a	_	_	
2-67	459-464	mouse	_	_	
2-68	464-465	,	_	_	
2-69	466-473	hamster	_	_	
2-70	474-477	and	_	_	
2-71	478-484	rabbit	_	_	
2-72	484-485	.	_	_	

#Text=Polyclonal antibodies are generally not identical, and thus usually recognize different epitopes or regions from the same antigen.
3-1	486-496	Polyclonal	_	_	
3-2	497-507	antibodies	_	_	
3-3	508-511	are	_	_	
3-4	512-521	generally	_	_	
3-5	522-525	not	_	_	
3-6	526-535	identical	_	_	
3-7	535-536	,	_	_	
3-8	537-540	and	_	_	
3-9	541-545	thus	_	_	
3-10	546-553	usually	_	_	
3-11	554-563	recognize	_	_	
3-12	564-573	different	_	_	
3-13	574-582	epitopes	_	_	
3-14	583-585	or	_	_	
3-15	586-593	regions	_	_	
3-16	594-598	from	_	_	
3-17	599-602	the	_	_	
3-18	603-607	same	_	_	
3-19	608-615	antigen	_	_	
3-20	615-616	.	_	_	

#Text=Thus, in such a case, typically a mixture (a composition) of different nucleic acids of the inventive polymeric carrier cargo complex will be used, each nucleic acid encoding a specific (monoclonal) antibody being directed to specific antigens or immunogens or epitopes of a protein.
#Text=[0179] According to a further alternative, the nucleic acid of the inventive polymeric carrier cargo complex may encode a monoclonal antibody.
4-1	617-621	Thus	_	_	
4-2	621-622	,	_	_	
4-3	623-625	in	_	_	
4-4	626-630	such	_	_	
4-5	631-632	a	_	_	
4-6	633-637	case	_	_	
4-7	637-638	,	_	_	
4-8	639-648	typically	_	_	
4-9	649-650	a	_	_	
4-10	651-658	mixture	_	_	
4-11	659-660	(	_	_	
4-12	660-661	a	_	_	
4-13	662-673	composition	_	_	
4-14	673-674	)	_	_	
4-15	675-677	of	_	_	
4-16	678-687	different	_	_	
4-17	688-695	nucleic	_	_	
4-18	696-701	acids	_	_	
4-19	702-704	of	_	_	
4-20	705-708	the	_	_	
4-21	709-718	inventive	_	_	
4-22	719-728	polymeric	_	_	
4-23	729-736	carrier	_	_	
4-24	737-742	cargo	_	_	
4-25	743-750	complex	_	_	
4-26	751-755	will	_	_	
4-27	756-758	be	_	_	
4-28	759-763	used	_	_	
4-29	763-764	,	_	_	
4-30	765-769	each	_	_	
4-31	770-777	nucleic	_	_	
4-32	778-782	acid	_	_	
4-33	783-791	encoding	_	_	
4-34	792-793	a	_	_	
4-35	794-802	specific	_	_	
4-36	803-804	(	_	_	
4-37	804-814	monoclonal	_	_	
4-38	814-815	)	_	_	
4-39	816-824	antibody	_	_	
4-40	825-830	being	_	_	
4-41	831-839	directed	_	_	
4-42	840-842	to	_	_	
4-43	843-851	specific	_	_	
4-44	852-860	antigens	_	_	
4-45	861-863	or	_	_	
4-46	864-874	immunogens	_	_	
4-47	875-877	or	_	_	
4-48	878-886	epitopes	_	_	
4-49	887-889	of	_	_	
4-50	890-891	a	_	_	
4-51	892-899	protein	_	_	
4-52	899-900	.	_	_	
4-53	901-902	[	_	_	
4-54	902-906	0179	_	_	
4-55	906-907	]	_	_	
4-56	908-917	According	_	_	
4-57	918-920	to	_	_	
4-58	921-922	a	_	_	
4-59	923-930	further	_	_	
4-60	931-942	alternative	_	_	
4-61	942-943	,	_	_	
4-62	944-947	the	_	_	
4-63	948-955	nucleic	_	_	
4-64	956-960	acid	_	_	
4-65	961-963	of	_	_	
4-66	964-967	the	_	_	
4-67	968-977	inventive	_	_	
4-68	978-987	polymeric	_	_	
4-69	988-995	carrier	_	_	
4-70	996-1001	cargo	_	_	
4-71	1002-1009	complex	_	_	
4-72	1010-1013	may	_	_	
4-73	1014-1020	encode	_	_	
4-74	1021-1022	a	_	_	
4-75	1023-1033	monoclonal	_	_	
4-76	1034-1042	antibody	_	_	
4-77	1042-1043	.	_	_	

#Text=The term "monoclonal antibody" herein typically refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.
5-1	1044-1047	The	_	_	
5-2	1048-1052	term	_	_	
5-3	1053-1054	"	_	_	
5-4	1054-1064	monoclonal	_	_	
5-5	1065-1073	antibody	_	_	
5-6	1073-1074	"	_	_	
5-7	1075-1081	herein	_	_	
5-8	1082-1091	typically	_	_	
5-9	1092-1098	refers	_	_	
5-10	1099-1101	to	_	_	
5-11	1102-1104	an	_	_	
5-12	1105-1113	antibody	_	_	
5-13	1114-1122	obtained	_	_	
5-14	1123-1127	from	_	_	
5-15	1128-1129	a	_	_	
5-16	1130-1140	population	_	_	
5-17	1141-1143	of	_	_	
5-18	1144-1157	substantially	_	_	
5-19	1158-1169	homogeneous	_	_	
5-20	1170-1180	antibodies	_	_	
5-21	1180-1181	,	_	_	
5-22	1182-1185	i.e	_	_	
5-23	1185-1186	.	_	_	
5-24	1186-1187	,	_	_	
5-25	1188-1191	the	_	_	
5-26	1192-1202	individual	_	_	
5-27	1203-1213	antibodies	_	_	
5-28	1214-1224	comprising	_	_	
5-29	1225-1228	the	_	_	
5-30	1229-1239	population	_	_	
5-31	1240-1243	are	_	_	
5-32	1244-1253	identical	_	_	
5-33	1254-1260	except	_	_	
5-34	1261-1264	for	_	_	
5-35	1265-1273	possible	_	_	
5-36	1274-1293	naturally-occurring	_	_	
5-37	1294-1303	mutations	_	_	
5-38	1304-1308	that	_	_	
5-39	1309-1312	may	_	_	
5-40	1313-1315	be	_	_	
5-41	1316-1323	present	_	_	
5-42	1324-1326	in	_	_	
5-43	1327-1332	minor	_	_	
5-44	1333-1340	amounts	_	_	
5-45	1340-1341	.	_	_	

#Text=Monoclonal antibodies are highly specific, being directed to a single antigenic site.
6-1	1342-1352	Monoclonal	_	_	
6-2	1353-1363	antibodies	_	_	
6-3	1364-1367	are	_	_	
6-4	1368-1374	highly	_	_	
6-5	1375-1383	specific	_	_	
6-6	1383-1384	,	_	_	
6-7	1385-1390	being	_	_	
6-8	1391-1399	directed	_	_	
6-9	1400-1402	to	_	_	
6-10	1403-1404	a	_	_	
6-11	1405-1411	single	_	_	
6-12	1412-1421	antigenic	_	_	
6-13	1422-1426	site	_	_	
6-14	1426-1427	.	_	_	

#Text=Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed to different determinants (epitopes), each monoclonal antibody is directed to a single determinant on the antigen.
7-1	1428-1439	Furthermore	_	_	
7-2	1439-1440	,	_	_	
7-3	1441-1443	in	_	_	
7-4	1444-1452	contrast	_	_	
7-5	1453-1455	to	_	_	
7-6	1456-1468	conventional	_	_	
7-7	1469-1470	(	_	_	
7-8	1470-1480	polyclonal	_	_	
7-9	1480-1481	)	_	_	
7-10	1482-1490	antibody	_	_	
7-11	1491-1503	preparations	_	_	
7-12	1504-1509	which	_	_	
7-13	1510-1519	typically	_	_	
7-14	1520-1527	include	_	_	
7-15	1528-1537	different	_	_	
7-16	1538-1548	antibodies	_	_	
7-17	1549-1557	directed	_	_	
7-18	1558-1560	to	_	_	
7-19	1561-1570	different	_	_	
7-20	1571-1583	determinants	_	_	
7-21	1584-1585	(	_	_	
7-22	1585-1593	epitopes	_	_	
7-23	1593-1594	)	_	_	
7-24	1594-1595	,	_	_	
7-25	1596-1600	each	_	_	
7-26	1601-1611	monoclonal	_	_	
7-27	1612-1620	antibody	_	_	
7-28	1621-1623	is	_	_	
7-29	1624-1632	directed	_	_	
7-30	1633-1635	to	_	_	
7-31	1636-1637	a	_	_	
7-32	1638-1644	single	_	_	
7-33	1645-1656	determinant	_	_	
7-34	1657-1659	on	_	_	
7-35	1660-1663	the	_	_	
7-36	1664-1671	antigen	_	_	
7-37	1671-1672	.	_	_	

#Text=For example, monoclonal antibodies as defined herein may be made by the hybridoma method first described by Kohler and Milstein, Nature, 256:495 (1975), or may be made by recombinant DNA methods, e.g. as described in U.S.
8-1	1673-1676	For	_	_	
8-2	1677-1684	example	_	_	
8-3	1684-1685	,	_	_	
8-4	1686-1696	monoclonal	_	_	
8-5	1697-1707	antibodies	_	_	
8-6	1708-1710	as	_	_	
8-7	1711-1718	defined	_	_	
8-8	1719-1725	herein	_	_	
8-9	1726-1729	may	_	_	
8-10	1730-1732	be	_	_	
8-11	1733-1737	made	_	_	
8-12	1738-1740	by	_	_	
8-13	1741-1744	the	_	_	
8-14	1745-1754	hybridoma	_	_	
8-15	1755-1761	method	_	_	
8-16	1762-1767	first	_	_	
8-17	1768-1777	described	_	_	
8-18	1778-1780	by	_	_	
8-19	1781-1787	Kohler	_	_	
8-20	1788-1791	and	_	_	
8-21	1792-1800	Milstein	_	_	
8-22	1800-1801	,	_	_	
8-23	1802-1808	Nature	_	_	
8-24	1808-1809	,	_	_	
8-25	1810-1813	256	_	_	
8-26	1813-1814	:	_	_	
8-27	1814-1817	495	_	_	
8-28	1818-1819	(	_	_	
8-29	1819-1823	1975	_	_	
8-30	1823-1824	)	_	_	
8-31	1824-1825	,	_	_	
8-32	1826-1828	or	_	_	
8-33	1829-1832	may	_	_	
8-34	1833-1835	be	_	_	
8-35	1836-1840	made	_	_	
8-36	1841-1843	by	_	_	
8-37	1844-1855	recombinant	_	_	
8-38	1856-1859	DNA	_	_	
8-39	1860-1867	methods	_	_	
8-40	1867-1868	,	_	_	
8-41	1869-1872	e.g	_	_	
8-42	1872-1873	.	_	_	
8-43	1874-1876	as	_	_	
8-44	1877-1886	described	_	_	
8-45	1887-1889	in	_	_	
8-46	1890-1893	U.S	_	_	
8-47	1893-1894	.	_	_	

#Text=Pat.
9-1	1895-1898	Pat	_	_	
9-2	1898-1899	.	_	_	

#Text=No. 4,816,567.
10-1	1900-1902	No	_	_	
10-2	1902-1903	.	_	_	
10-3	1904-1913	4,816,567	_	_	
10-4	1913-1914	.	_	_	

#Text="Monoclonal antibodies" may also be isolated from phage libraries generated using the techniques described in McCafferty et al., Nature, 348:552-554 (1990), for example.
11-1	1915-1916	"	_	_	
11-2	1916-1926	Monoclonal	_	_	
11-3	1927-1937	antibodies	_	_	
11-4	1937-1938	"	_	_	
11-5	1939-1942	may	_	_	
11-6	1943-1947	also	_	_	
11-7	1948-1950	be	_	_	
11-8	1951-1959	isolated	_	_	
11-9	1960-1964	from	_	_	
11-10	1965-1970	phage	_	_	
11-11	1971-1980	libraries	_	_	
11-12	1981-1990	generated	_	_	
11-13	1991-1996	using	_	_	
11-14	1997-2000	the	_	_	
11-15	2001-2011	techniques	_	_	
11-16	2012-2021	described	_	_	
11-17	2022-2024	in	_	_	
11-18	2025-2035	McCafferty	_	_	
11-19	2036-2038	et	_	_	
11-20	2039-2041	al	_	_	
11-21	2041-2042	.	_	_	
11-22	2042-2043	,	_	_	
11-23	2044-2050	Nature	_	_	
11-24	2050-2051	,	_	_	
11-25	2052-2055	348	_	_	
11-26	2055-2056	:	_	_	
11-27	2056-2059	552	_	_	
11-28	2059-2060	-	_	_	
11-29	2060-2063	554	_	_	
11-30	2064-2065	(	_	_	
11-31	2065-2069	1990	_	_	
11-32	2069-2070	)	_	_	
11-33	2070-2071	,	_	_	
11-34	2072-2075	for	_	_	
11-35	2076-2083	example	_	_	
11-36	2083-2084	.	_	_	

#Text=According to Kohler and Milstein, an immunogen (antigen) of interest is injected into a host such as a mouse and B-cell lymphocytes produced in response to the immunogen are harvested after a period of time.
12-1	2085-2094	According	_	_	
12-2	2095-2097	to	_	_	
12-3	2098-2104	Kohler	_	_	
12-4	2105-2108	and	_	_	
12-5	2109-2117	Milstein	_	_	
12-6	2117-2118	,	_	_	
12-7	2119-2121	an	_	_	
12-8	2122-2131	immunogen	_	_	
12-9	2132-2133	(	_	_	
12-10	2133-2140	antigen	_	_	
12-11	2140-2141	)	_	_	
12-12	2142-2144	of	_	_	
12-13	2145-2153	interest	_	_	
12-14	2154-2156	is	_	_	
12-15	2157-2165	injected	_	_	
12-16	2166-2170	into	_	_	
12-17	2171-2172	a	_	_	
12-18	2173-2177	host	_	_	
12-19	2178-2182	such	_	_	
12-20	2183-2185	as	_	_	
12-21	2186-2187	a	_	_	
12-22	2188-2193	mouse	_	_	
12-23	2194-2197	and	_	_	
12-24	2198-2204	B-cell	_	_	
12-25	2205-2216	lymphocytes	_	_	
12-26	2217-2225	produced	_	_	
12-27	2226-2228	in	_	_	
12-28	2229-2237	response	_	_	
12-29	2238-2240	to	_	_	
12-30	2241-2244	the	_	_	
12-31	2245-2254	immunogen	_	_	
12-32	2255-2258	are	_	_	
12-33	2259-2268	harvested	_	_	
12-34	2269-2274	after	_	_	
12-35	2275-2276	a	_	_	
12-36	2277-2283	period	_	_	
12-37	2284-2286	of	_	_	
12-38	2287-2291	time	_	_	
12-39	2291-2292	.	_	_	

#Text=The B-cells are combined with myeloma cells obtained from mouse and introduced into a medium which permits the B-cells to fuse with the myeloma cells, producing hybridomas.
13-1	2293-2296	The	_	_	
13-2	2297-2304	B-cells	_	_	
13-3	2305-2308	are	_	_	
13-4	2309-2317	combined	_	_	
13-5	2318-2322	with	_	_	
13-6	2323-2330	myeloma	_	_	
13-7	2331-2336	cells	_	_	
13-8	2337-2345	obtained	_	_	
13-9	2346-2350	from	_	_	
13-10	2351-2356	mouse	_	_	
13-11	2357-2360	and	_	_	
13-12	2361-2371	introduced	_	_	
13-13	2372-2376	into	_	_	
13-14	2377-2378	a	_	_	
13-15	2379-2385	medium	_	_	
13-16	2386-2391	which	_	_	
13-17	2392-2399	permits	_	_	
13-18	2400-2403	the	_	_	
13-19	2404-2411	B-cells	_	_	
13-20	2412-2414	to	_	_	
13-21	2415-2419	fuse	_	_	
13-22	2420-2424	with	_	_	
13-23	2425-2428	the	_	_	
13-24	2429-2436	myeloma	_	_	
13-25	2437-2442	cells	_	_	
13-26	2442-2443	,	_	_	
13-27	2444-2453	producing	_	_	
13-28	2454-2464	hybridomas	_	_	
13-29	2464-2465	.	_	_	

#Text=These fused cells (hybridomas) are then placed into separate wells of microliter plates and grown to produce monoclonal antibodies.
14-1	2466-2471	These	_	_	
14-2	2472-2477	fused	_	_	
14-3	2478-2483	cells	_	_	
14-4	2484-2485	(	_	_	
14-5	2485-2495	hybridomas	_	_	
14-6	2495-2496	)	_	_	
14-7	2497-2500	are	_	_	
14-8	2501-2505	then	_	_	
14-9	2506-2512	placed	_	_	
14-10	2513-2517	into	_	_	
14-11	2518-2526	separate	_	_	
14-12	2527-2532	wells	_	_	
14-13	2533-2535	of	_	_	
14-14	2536-2546	microliter	_	_	
14-15	2547-2553	plates	_	_	
14-16	2554-2557	and	_	_	
14-17	2558-2563	grown	_	_	
14-18	2564-2566	to	_	_	
14-19	2567-2574	produce	_	_	
14-20	2575-2585	monoclonal	_	_	
14-21	2586-2596	antibodies	_	_	
14-22	2596-2597	.	_	_	

#Text=The monoclonal antibodies are tested to determine which of them are suitable for detecting the antigen of interest.
15-1	2598-2601	The	_	_	
15-2	2602-2612	monoclonal	_	_	
15-3	2613-2623	antibodies	_	_	
15-4	2624-2627	are	_	_	
15-5	2628-2634	tested	_	_	
15-6	2635-2637	to	_	_	
15-7	2638-2647	determine	_	_	
15-8	2648-2653	which	_	_	
15-9	2654-2656	of	_	_	
15-10	2657-2661	them	_	_	
15-11	2662-2665	are	_	_	
15-12	2666-2674	suitable	_	_	
15-13	2675-2678	for	_	_	
15-14	2679-2688	detecting	_	_	
15-15	2689-2692	the	_	_	
15-16	2693-2700	antigen	_	_	
15-17	2701-2703	of	_	_	
15-18	2704-2712	interest	_	_	
15-19	2712-2713	.	_	_	

#Text=After being selected, the monoclonal antibodies can be grown in cell cultures or by injecting the hybridomas into mice.
16-1	2714-2719	After	_	_	
16-2	2720-2725	being	_	_	
16-3	2726-2734	selected	_	_	
16-4	2734-2735	,	_	_	
16-5	2736-2739	the	_	_	
16-6	2740-2750	monoclonal	_	_	
16-7	2751-2761	antibodies	_	_	
16-8	2762-2765	can	_	_	
16-9	2766-2768	be	_	_	
16-10	2769-2774	grown	_	_	
16-11	2775-2777	in	_	_	
16-12	2778-2782	cell	_	_	
16-13	2783-2791	cultures	_	_	
16-14	2792-2794	or	_	_	
16-15	2795-2797	by	_	_	
16-16	2798-2807	injecting	_	_	
16-17	2808-2811	the	_	_	
16-18	2812-2822	hybridomas	_	_	
16-19	2823-2827	into	_	_	
16-20	2828-2832	mice	_	_	
16-21	2832-2833	.	_	_	

#Text=However, for the purposes of the present invention, the peptide sequences of these monoclonal antibodies have to be sequenced and the nucleic acid sequences encoding these antibodies can be present as the nucleic acid of the inventive polymeric carrier cargo complex formed by the nucleic acid cargo and a polymeric carrier molecule according to generic formula (I) (or according to any of its subformulas herein).
#Text=[0180] For therapeutical purposes in humans, non-human monoclonal or polyclonal antibodies, such as murine antibodies may also be encoded by the nucleic acid of the inventive polymeric carrier cargo complex formed by the nucleic acid cargo and a polymeric carrier molecule according to generic formula (I) (or according to any of its subformulas herein).
17-1	2834-2841	However	_	_	
17-2	2841-2842	,	_	_	
17-3	2843-2846	for	_	_	
17-4	2847-2850	the	_	_	
17-5	2851-2859	purposes	_	_	
17-6	2860-2862	of	_	_	
17-7	2863-2866	the	_	_	
17-8	2867-2874	present	_	_	
17-9	2875-2884	invention	_	_	
17-10	2884-2885	,	_	_	
17-11	2886-2889	the	_	_	
17-12	2890-2897	peptide	_	_	
17-13	2898-2907	sequences	_	_	
17-14	2908-2910	of	_	_	
17-15	2911-2916	these	_	_	
17-16	2917-2927	monoclonal	_	_	
17-17	2928-2938	antibodies	_	_	
17-18	2939-2943	have	_	_	
17-19	2944-2946	to	_	_	
17-20	2947-2949	be	_	_	
17-21	2950-2959	sequenced	_	_	
17-22	2960-2963	and	_	_	
17-23	2964-2967	the	_	_	
17-24	2968-2975	nucleic	_	_	
17-25	2976-2980	acid	_	_	
17-26	2981-2990	sequences	_	_	
17-27	2991-2999	encoding	_	_	
17-28	3000-3005	these	_	_	
17-29	3006-3016	antibodies	_	_	
17-30	3017-3020	can	_	_	
17-31	3021-3023	be	_	_	
17-32	3024-3031	present	_	_	
17-33	3032-3034	as	_	_	
17-34	3035-3038	the	_	_	
17-35	3039-3046	nucleic	_	_	
17-36	3047-3051	acid	_	_	
17-37	3052-3054	of	_	_	
17-38	3055-3058	the	_	_	
17-39	3059-3068	inventive	_	_	
17-40	3069-3078	polymeric	_	_	
17-41	3079-3086	carrier	_	_	
17-42	3087-3092	cargo	_	_	
17-43	3093-3100	complex	_	_	
17-44	3101-3107	formed	_	_	
17-45	3108-3110	by	_	_	
17-46	3111-3114	the	_	_	
17-47	3115-3122	nucleic	_	_	
17-48	3123-3127	acid	_	_	
17-49	3128-3133	cargo	_	_	
17-50	3134-3137	and	_	_	
17-51	3138-3139	a	_	_	
17-52	3140-3149	polymeric	_	_	
17-53	3150-3157	carrier	_	_	
17-54	3158-3166	molecule	_	_	
17-55	3167-3176	according	_	_	
17-56	3177-3179	to	_	_	
17-57	3180-3187	generic	_	_	
17-58	3188-3195	formula	_	_	
17-59	3196-3197	(	_	_	
17-60	3197-3198	I	_	_	
17-61	3198-3199	)	_	_	
17-62	3200-3201	(	_	_	
17-63	3201-3203	or	_	_	
17-64	3204-3213	according	_	_	
17-65	3214-3216	to	_	_	
17-66	3217-3220	any	_	_	
17-67	3221-3223	of	_	_	
17-68	3224-3227	its	_	_	
17-69	3228-3239	subformulas	_	_	
17-70	3240-3246	herein	_	_	
17-71	3246-3247	)	_	_	
17-72	3247-3248	.	_	_	
17-73	3249-3250	[	_	_	
17-74	3250-3254	0180	_	_	
17-75	3254-3255	]	_	_	
17-76	3256-3259	For	_	_	
17-77	3260-3273	therapeutical	_	_	
17-78	3274-3282	purposes	_	_	
17-79	3283-3285	in	_	_	
17-80	3286-3292	humans	_	_	
17-81	3292-3293	,	_	_	
17-82	3294-3303	non-human	_	_	
17-83	3304-3314	monoclonal	_	_	
17-84	3315-3317	or	_	_	
17-85	3318-3328	polyclonal	_	_	
17-86	3329-3339	antibodies	_	_	
17-87	3339-3340	,	_	_	
17-88	3341-3345	such	_	_	
17-89	3346-3348	as	_	_	
17-90	3349-3355	murine	_	_	
17-91	3356-3366	antibodies	_	_	
17-92	3367-3370	may	_	_	
17-93	3371-3375	also	_	_	
17-94	3376-3378	be	_	_	
17-95	3379-3386	encoded	_	_	
17-96	3387-3389	by	_	_	
17-97	3390-3393	the	_	_	
17-98	3394-3401	nucleic	_	_	
17-99	3402-3406	acid	_	_	
17-100	3407-3409	of	_	_	
17-101	3410-3413	the	_	_	
17-102	3414-3423	inventive	_	_	
17-103	3424-3433	polymeric	_	_	
17-104	3434-3441	carrier	_	_	
17-105	3442-3447	cargo	_	_	
17-106	3448-3455	complex	_	_	
17-107	3456-3462	formed	_	_	
17-108	3463-3465	by	_	_	
17-109	3466-3469	the	_	_	
17-110	3470-3477	nucleic	_	_	
17-111	3478-3482	acid	_	_	
17-112	3483-3488	cargo	_	_	
17-113	3489-3492	and	_	_	
17-114	3493-3494	a	_	_	
17-115	3495-3504	polymeric	_	_	
17-116	3505-3512	carrier	_	_	
17-117	3513-3521	molecule	_	_	
17-118	3522-3531	according	_	_	
17-119	3532-3534	to	_	_	
17-120	3535-3542	generic	_	_	
17-121	3543-3550	formula	_	_	
17-122	3551-3552	(	_	_	
17-123	3552-3553	I	_	_	
17-124	3553-3554	)	_	_	
17-125	3555-3556	(	_	_	
17-126	3556-3558	or	_	_	
17-127	3559-3568	according	_	_	
17-128	3569-3571	to	_	_	
17-129	3572-3575	any	_	_	
17-130	3576-3578	of	_	_	
17-131	3579-3582	its	_	_	
17-132	3583-3594	subformulas	_	_	
17-133	3595-3601	herein	_	_	
17-134	3601-3602	)	_	_	
17-135	3602-3603	.	_	_	

#Text=However, such antibodies are typically only of limited use, since they generally induce an immune response by production of human antibodies directed to the said non-human antibodies, in the human body.
18-1	3604-3611	However	*[1]	20-3[2_1]	
18-2	3611-3612	,	*[1]	_	
18-3	3613-3617	such	*[1]	_	
18-4	3618-3628	antibodies	*[1]	_	
18-5	3629-3632	are	*[1]	_	
18-6	3633-3642	typically	*[1]	_	
18-7	3643-3647	only	*[1]	_	
18-8	3648-3650	of	*[1]	_	
18-9	3651-3658	limited	*[1]	_	
18-10	3659-3662	use	*[1]	_	
18-11	3662-3663	,	*[1]	_	
18-12	3664-3669	since	*[1]	_	
18-13	3670-3674	they	*[1]	_	
18-14	3675-3684	generally	*[1]	_	
18-15	3685-3691	induce	*[1]	_	
18-16	3692-3694	an	*[1]	_	
18-17	3695-3701	immune	*[1]	_	
18-18	3702-3710	response	*[1]	_	
18-19	3711-3713	by	*[1]	_	
18-20	3714-3724	production	*[1]	_	
18-21	3725-3727	of	*[1]	_	
18-22	3728-3733	human	*[1]	_	
18-23	3734-3744	antibodies	*[1]	_	
18-24	3745-3753	directed	*[1]	_	
18-25	3754-3756	to	*[1]	_	
18-26	3757-3760	the	*[1]	_	
18-27	3761-3765	said	*[1]	_	
18-28	3766-3775	non-human	*[1]	_	
18-29	3776-3786	antibodies	*[1]	_	
18-30	3786-3787	,	*[1]	_	
18-31	3788-3790	in	*[1]	_	
18-32	3791-3794	the	*[1]	_	
18-33	3795-3800	human	*[1]	_	
18-34	3801-3805	body	*[1]	_	
18-35	3805-3806	.	*[1]	_	

#Text=Therefore, a particular non-human antibody can only be administered once to the human.
19-1	3807-3816	Therefore	_	_	
19-2	3816-3817	,	_	_	
19-3	3818-3819	a	_	_	
19-4	3820-3830	particular	_	_	
19-5	3831-3840	non-human	_	_	
19-6	3841-3849	antibody	_	_	
19-7	3850-3853	can	_	_	
19-8	3854-3858	only	_	_	
19-9	3859-3861	be	_	_	
19-10	3862-3874	administered	_	_	
19-11	3875-3879	once	_	_	
19-12	3880-3882	to	_	_	
19-13	3883-3886	the	_	_	
19-14	3887-3892	human	_	_	
19-15	3892-3893	.	_	_	

#Text=To solve this problem, chimeric, humanized non-human and human antibodies are also envisaged encoded by the nucleic acid of the inventive polymeric carrier cargo complex.
20-1	3894-3896	To	_	_	
20-2	3897-3902	solve	_	_	
20-3	3903-3907	this	*[2]	_	
20-4	3908-3915	problem	*[2]	_	
20-5	3915-3916	,	_	_	
20-6	3917-3925	chimeric	_	_	
20-7	3925-3926	,	_	_	
20-8	3927-3936	humanized	_	_	
20-9	3937-3946	non-human	_	_	
20-10	3947-3950	and	_	_	
20-11	3951-3956	human	_	_	
20-12	3957-3967	antibodies	_	_	
20-13	3968-3971	are	_	_	
20-14	3972-3976	also	_	_	
20-15	3977-3986	envisaged	_	_	
20-16	3987-3994	encoded	_	_	
20-17	3995-3997	by	_	_	
20-18	3998-4001	the	_	_	
20-19	4002-4009	nucleic	_	_	
20-20	4010-4014	acid	_	_	
20-21	4015-4017	of	_	_	
20-22	4018-4021	the	_	_	
20-23	4022-4031	inventive	_	_	
20-24	4032-4041	polymeric	_	_	
20-25	4042-4049	carrier	_	_	
20-26	4050-4055	cargo	_	_	
20-27	4056-4063	complex	_	_	
20-28	4063-4064	.	_	_	

#Text="Chimeric" antibodies, which may be encoded by the nucleic acid according to the present invention, are preferably antibodies in which the constant domains of an antibody described above are replaced by sequences of antibodies from other organisms, preferably human sequences.
21-1	4065-4066	"	_	_	
21-2	4066-4074	Chimeric	_	_	
21-3	4074-4075	"	_	_	
21-4	4076-4086	antibodies	_	_	
21-5	4086-4087	,	_	_	
21-6	4088-4093	which	_	_	
21-7	4094-4097	may	_	_	
21-8	4098-4100	be	_	_	
21-9	4101-4108	encoded	_	_	
21-10	4109-4111	by	_	_	
21-11	4112-4115	the	_	_	
21-12	4116-4123	nucleic	_	_	
21-13	4124-4128	acid	_	_	
21-14	4129-4138	according	_	_	
21-15	4139-4141	to	_	_	
21-16	4142-4145	the	_	_	
21-17	4146-4153	present	_	_	
21-18	4154-4163	invention	_	_	
21-19	4163-4164	,	_	_	
21-20	4165-4168	are	_	_	
21-21	4169-4179	preferably	_	_	
21-22	4180-4190	antibodies	_	_	
21-23	4191-4193	in	_	_	
21-24	4194-4199	which	_	_	
21-25	4200-4203	the	_	_	
21-26	4204-4212	constant	_	_	
21-27	4213-4220	domains	_	_	
21-28	4221-4223	of	_	_	
21-29	4224-4226	an	_	_	
21-30	4227-4235	antibody	_	_	
21-31	4236-4245	described	_	_	
21-32	4246-4251	above	_	_	
21-33	4252-4255	are	_	_	
21-34	4256-4264	replaced	_	_	
21-35	4265-4267	by	_	_	
21-36	4268-4277	sequences	_	_	
21-37	4278-4280	of	_	_	
21-38	4281-4291	antibodies	_	_	
21-39	4292-4296	from	_	_	
21-40	4297-4302	other	_	_	
21-41	4303-4312	organisms	_	_	
21-42	4312-4313	,	_	_	
21-43	4314-4324	preferably	_	_	
21-44	4325-4330	human	_	_	
21-45	4331-4340	sequences	_	_	
21-46	4340-4341	.	_	_	

#Text="Humanized" (non-human) antibodies, which may be also encoded by nucleic acid according to the present invention, are antibodies in which the constant and variable domains (except for the hypervariable domains) described above of an antibody are replaced by human sequences.
22-1	4342-4343	"	_	_	
22-2	4343-4352	Humanized	_	_	
22-3	4352-4353	"	_	_	
22-4	4354-4355	(	_	_	
22-5	4355-4364	non-human	_	_	
22-6	4364-4365	)	_	_	
22-7	4366-4376	antibodies	_	_	
22-8	4376-4377	,	_	_	
22-9	4378-4383	which	_	_	
22-10	4384-4387	may	_	_	
22-11	4388-4390	be	_	_	
22-12	4391-4395	also	_	_	
22-13	4396-4403	encoded	_	_	
22-14	4404-4406	by	_	_	
22-15	4407-4414	nucleic	_	_	
22-16	4415-4419	acid	_	_	
22-17	4420-4429	according	_	_	
22-18	4430-4432	to	_	_	
22-19	4433-4436	the	_	_	
22-20	4437-4444	present	_	_	
22-21	4445-4454	invention	_	_	
22-22	4454-4455	,	_	_	
22-23	4456-4459	are	_	_	
22-24	4460-4470	antibodies	_	_	
22-25	4471-4473	in	_	_	
22-26	4474-4479	which	_	_	
22-27	4480-4483	the	_	_	
22-28	4484-4492	constant	_	_	
22-29	4493-4496	and	_	_	
22-30	4497-4505	variable	_	_	
22-31	4506-4513	domains	_	_	
22-32	4514-4515	(	_	_	
22-33	4515-4521	except	_	_	
22-34	4522-4525	for	_	_	
22-35	4526-4529	the	_	_	
22-36	4530-4543	hypervariable	_	_	
22-37	4544-4551	domains	_	_	
22-38	4551-4552	)	_	_	
22-39	4553-4562	described	_	_	
22-40	4563-4568	above	_	_	
22-41	4569-4571	of	_	_	
22-42	4572-4574	an	_	_	
22-43	4575-4583	antibody	_	_	
22-44	4584-4587	are	_	_	
22-45	4588-4596	replaced	_	_	
22-46	4597-4599	by	_	_	
22-47	4600-4605	human	_	_	
22-48	4606-4615	sequences	_	_	
22-49	4615-4616	.	_	_	

#Text=According to another alternative, the nucleic acid according to the present invention may encode human antibodies, i.e. antibodies having only human sequences.
23-1	4617-4626	According	_	_	
23-2	4627-4629	to	_	_	
23-3	4630-4637	another	_	_	
23-4	4638-4649	alternative	_	_	
23-5	4649-4650	,	_	_	
23-6	4651-4654	the	_	_	
23-7	4655-4662	nucleic	_	_	
23-8	4663-4667	acid	_	_	
23-9	4668-4677	according	_	_	
23-10	4678-4680	to	_	_	
23-11	4681-4684	the	_	_	
23-12	4685-4692	present	_	_	
23-13	4693-4702	invention	_	_	
23-14	4703-4706	may	_	_	
23-15	4707-4713	encode	_	_	
23-16	4714-4719	human	_	_	
23-17	4720-4730	antibodies	_	_	
23-18	4730-4731	,	_	_	
23-19	4732-4735	i.e	_	_	
23-20	4735-4736	.	_	_	
23-21	4737-4747	antibodies	_	_	
23-22	4748-4754	having	_	_	
23-23	4755-4759	only	_	_	
23-24	4760-4765	human	_	_	
23-25	4766-4775	sequences	_	_	
23-26	4775-4776	.	_	_	

#Text=Such human antibodies can be isolated from human tissues or from immunized non-human host organisms which are transgene for the human IgG gene locus, and nucleic acid sequences may be prepared according to procedures well known in the art.
24-1	4777-4781	Such	_	_	
24-2	4782-4787	human	_	_	
24-3	4788-4798	antibodies	_	_	
24-4	4799-4802	can	_	_	
24-5	4803-4805	be	_	_	
24-6	4806-4814	isolated	_	_	
24-7	4815-4819	from	_	_	
24-8	4820-4825	human	_	_	
24-9	4826-4833	tissues	_	_	
24-10	4834-4836	or	_	_	
24-11	4837-4841	from	_	_	
24-12	4842-4851	immunized	_	_	
24-13	4852-4861	non-human	_	_	
24-14	4862-4866	host	_	_	
24-15	4867-4876	organisms	_	_	
24-16	4877-4882	which	_	_	
24-17	4883-4886	are	_	_	
24-18	4887-4896	transgene	_	_	
24-19	4897-4900	for	_	_	
24-20	4901-4904	the	_	_	
24-21	4905-4910	human	_	_	
24-22	4911-4914	IgG	_	_	
24-23	4915-4919	gene	_	_	
24-24	4920-4925	locus	_	_	
24-25	4925-4926	,	_	_	
24-26	4927-4930	and	_	_	
24-27	4931-4938	nucleic	_	_	
24-28	4939-4943	acid	_	_	
24-29	4944-4953	sequences	_	_	
24-30	4954-4957	may	_	_	
24-31	4958-4960	be	_	_	
24-32	4961-4969	prepared	_	_	
24-33	4970-4979	according	_	_	
24-34	4980-4982	to	_	_	
24-35	4983-4993	procedures	_	_	
24-36	4994-4998	well	_	_	
24-37	4999-5004	known	_	_	
24-38	5005-5007	in	_	_	
24-39	5008-5011	the	_	_	
24-40	5012-5015	art	_	_	
24-41	5015-5016	.	_	_	

#Text=Additionally, human antibodies can be provided by the use of a phage display.
#Text=[0181] In addition, the nucleic acid of the inventive polymeric carrier cargo complex may encode bispecific antibodies.
25-1	5017-5029	Additionally	_	_	
25-2	5029-5030	,	_	_	
25-3	5031-5036	human	_	_	
25-4	5037-5047	antibodies	_	_	
25-5	5048-5051	can	_	_	
25-6	5052-5054	be	_	_	
25-7	5055-5063	provided	_	_	
25-8	5064-5066	by	_	_	
25-9	5067-5070	the	_	_	
25-10	5071-5074	use	_	_	
25-11	5075-5077	of	_	_	
25-12	5078-5079	a	_	_	
25-13	5080-5085	phage	_	_	
25-14	5086-5093	display	_	_	
25-15	5093-5094	.	_	_	
25-16	5095-5096	[	_	_	
25-17	5096-5100	0181	_	_	
25-18	5100-5101	]	_	_	
25-19	5102-5104	In	_	_	
25-20	5105-5113	addition	_	_	
25-21	5113-5114	,	_	_	
25-22	5115-5118	the	_	_	
25-23	5119-5126	nucleic	_	_	
25-24	5127-5131	acid	_	_	
25-25	5132-5134	of	_	_	
25-26	5135-5138	the	_	_	
25-27	5139-5148	inventive	_	_	
25-28	5149-5158	polymeric	_	_	
25-29	5159-5166	carrier	_	_	
25-30	5167-5172	cargo	_	_	
25-31	5173-5180	complex	_	_	
25-32	5181-5184	may	_	_	
25-33	5185-5191	encode	_	_	
25-34	5192-5202	bispecific	_	_	
25-35	5203-5213	antibodies	_	_	
25-36	5213-5214	.	_	_	

#Text="Bispecific" antibodies in context of the invention are preferably antibodies which act as an adaptor between an effector and a respective target by two different F.sub.a/b-domains, e.g. for the purposes of recruiting effector molecules such as toxins, drugs, cytokines etc., targeting effector cells such as CTL, NK cells, makrophages, granulocytes, etc.
26-1	5215-5216	"	_	_	
26-2	5216-5226	Bispecific	_	_	
26-3	5226-5227	"	_	_	
26-4	5228-5238	antibodies	_	_	
26-5	5239-5241	in	_	_	
26-6	5242-5249	context	_	_	
26-7	5250-5252	of	_	_	
26-8	5253-5256	the	_	_	
26-9	5257-5266	invention	_	_	
26-10	5267-5270	are	_	_	
26-11	5271-5281	preferably	_	_	
26-12	5282-5292	antibodies	_	_	
26-13	5293-5298	which	_	_	
26-14	5299-5302	act	_	_	
26-15	5303-5305	as	_	_	
26-16	5306-5308	an	_	_	
26-17	5309-5316	adaptor	_	_	
26-18	5317-5324	between	_	_	
26-19	5325-5327	an	_	_	
26-20	5328-5336	effector	_	_	
26-21	5337-5340	and	_	_	
26-22	5341-5342	a	_	_	
26-23	5343-5353	respective	_	_	
26-24	5354-5360	target	_	_	
26-25	5361-5363	by	_	_	
26-26	5364-5367	two	_	_	
26-27	5368-5377	different	_	_	
26-28	5378-5385	F.sub.a	_	_	
26-29	5385-5386	/	_	_	
26-30	5386-5395	b-domains	_	_	
26-31	5395-5396	,	_	_	
26-32	5397-5400	e.g	_	_	
26-33	5400-5401	.	_	_	
26-34	5402-5405	for	_	_	
26-35	5406-5409	the	_	_	
26-36	5410-5418	purposes	_	_	
26-37	5419-5421	of	_	_	
26-38	5422-5432	recruiting	_	_	
26-39	5433-5441	effector	_	_	
26-40	5442-5451	molecules	_	_	
26-41	5452-5456	such	_	_	
26-42	5457-5459	as	_	_	
26-43	5460-5466	toxins	_	_	
26-44	5466-5467	,	_	_	
26-45	5468-5473	drugs	_	_	
26-46	5473-5474	,	_	_	
26-47	5475-5484	cytokines	_	_	
26-48	5485-5488	etc	_	_	
26-49	5488-5489	.	_	_	
26-50	5489-5490	,	_	_	
26-51	5491-5500	targeting	_	_	
26-52	5501-5509	effector	_	_	
26-53	5510-5515	cells	_	_	
26-54	5516-5520	such	_	_	
26-55	5521-5523	as	_	_	
26-56	5524-5527	CTL	_	_	
26-57	5527-5528	,	_	_	
26-58	5529-5531	NK	_	_	
26-59	5532-5537	cells	_	_	
26-60	5537-5538	,	_	_	
26-61	5539-5550	makrophages	_	_	
26-62	5550-5551	,	_	_	
26-63	5552-5564	granulocytes	_	_	
26-64	5564-5565	,	_	_	
26-65	5566-5569	etc	_	_	
26-66	5569-5570	.	_	_	

#Text=(see for review: Kontermann R.
27-1	5571-5572	(	_	_	
27-2	5572-5575	see	_	_	
27-3	5576-5579	for	_	_	
27-4	5580-5586	review	_	_	
27-5	5586-5587	:	_	_	
27-6	5588-5598	Kontermann	_	_	
27-7	5599-5600	R	_	_	
27-8	5600-5601	.	_	_	

#Text=E., Acta Pharmacol.
28-1	5602-5603	E	_	_	
28-2	5603-5604	.	_	_	
28-3	5604-5605	,	_	_	
28-4	5606-5610	Acta	_	_	
28-5	5611-5620	Pharmacol	_	_	
28-6	5620-5621	.	_	_	

#Text=Sin, 2005, 26(1): 1-9).
29-1	5622-5625	Sin	_	_	
29-2	5625-5626	,	_	_	
29-3	5627-5631	2005	_	_	
29-4	5631-5632	,	_	_	
29-5	5633-5635	26	_	_	
29-6	5635-5636	(	_	_	
29-7	5636-5637	1	_	_	
29-8	5637-5638	)	_	_	
29-9	5638-5639	:	_	_	
29-10	5640-5641	1	_	_	
29-11	5641-5642	-	_	_	
29-12	5642-5643	9	_	_	
29-13	5643-5644	)	_	_	
29-14	5644-5645	.	_	_	

#Text=Bispecific antibodies as defined herein are, in general, configured to recognize by two different F.sub.a/b-domains, e.g. two different antigens, immunogens, epitopes, drugs, cells (or receptors on cells), or other molecules (or structures) as defined herein.
30-1	5646-5656	Bispecific	_	_	
30-2	5657-5667	antibodies	_	_	
30-3	5668-5670	as	_	_	
30-4	5671-5678	defined	_	_	
30-5	5679-5685	herein	_	_	
30-6	5686-5689	are	_	_	
30-7	5689-5690	,	_	_	
30-8	5691-5693	in	_	_	
30-9	5694-5701	general	_	_	
30-10	5701-5702	,	_	_	
30-11	5703-5713	configured	_	_	
30-12	5714-5716	to	_	_	
30-13	5717-5726	recognize	_	_	
30-14	5727-5729	by	_	_	
30-15	5730-5733	two	_	_	
30-16	5734-5743	different	_	_	
30-17	5744-5751	F.sub.a	_	_	
30-18	5751-5752	/	_	_	
30-19	5752-5761	b-domains	_	_	
30-20	5761-5762	,	_	_	
30-21	5763-5766	e.g	_	_	
30-22	5766-5767	.	_	_	
30-23	5768-5771	two	_	_	
30-24	5772-5781	different	_	_	
30-25	5782-5790	antigens	_	_	
30-26	5790-5791	,	_	_	
30-27	5792-5802	immunogens	_	_	
30-28	5802-5803	,	_	_	
30-29	5804-5812	epitopes	_	_	
30-30	5812-5813	,	_	_	
30-31	5814-5819	drugs	_	_	
30-32	5819-5820	,	_	_	
30-33	5821-5826	cells	_	_	
30-34	5827-5828	(	_	_	
30-35	5828-5830	or	_	_	
30-36	5831-5840	receptors	_	_	
30-37	5841-5843	on	_	_	
30-38	5844-5849	cells	_	_	
30-39	5849-5850	)	_	_	
30-40	5850-5851	,	_	_	
30-41	5852-5854	or	_	_	
30-42	5855-5860	other	_	_	
30-43	5861-5870	molecules	_	_	
30-44	5871-5872	(	_	_	
30-45	5872-5874	or	_	_	
30-46	5875-5885	structures	_	_	
30-47	5885-5886	)	_	_	
30-48	5887-5889	as	_	_	
30-49	5890-5897	defined	_	_	
30-50	5898-5904	herein	_	_	
30-51	5904-5905	.	_	_	

#Text=Bispecificity means herewith that the antigen-binding regions of the antibodies are specific for two different epitopes.
31-1	5906-5919	Bispecificity	_	_	
31-2	5920-5925	means	_	_	
31-3	5926-5934	herewith	_	_	
31-4	5935-5939	that	_	_	
31-5	5940-5943	the	_	_	
31-6	5944-5959	antigen-binding	_	_	
31-7	5960-5967	regions	_	_	
31-8	5968-5970	of	_	_	
31-9	5971-5974	the	_	_	
31-10	5975-5985	antibodies	_	_	
31-11	5986-5989	are	_	_	
31-12	5990-5998	specific	_	_	
31-13	5999-6002	for	_	_	
31-14	6003-6006	two	_	_	
31-15	6007-6016	different	_	_	
31-16	6017-6025	epitopes	_	_	
31-17	6025-6026	.	_	_	

#Text=Thus, different antigens, immunogens or epitopes, etc. can be brought close together, what, optionally, allows a direct interaction of the two components.
32-1	6027-6031	Thus	_	_	
32-2	6031-6032	,	_	_	
32-3	6033-6042	different	_	_	
32-4	6043-6051	antigens	_	_	
32-5	6051-6052	,	_	_	
32-6	6053-6063	immunogens	_	_	
32-7	6064-6066	or	_	_	
32-8	6067-6075	epitopes	_	_	
32-9	6075-6076	,	_	_	
32-10	6077-6080	etc	_	_	
32-11	6080-6081	.	_	_	
32-12	6082-6085	can	_	_	
32-13	6086-6088	be	_	_	
32-14	6089-6096	brought	_	_	
32-15	6097-6102	close	_	_	
32-16	6103-6111	together	_	_	
32-17	6111-6112	,	_	_	
32-18	6113-6117	what	_	_	
32-19	6117-6118	,	_	_	
32-20	6119-6129	optionally	_	_	
32-21	6129-6130	,	_	_	
32-22	6131-6137	allows	_	_	
32-23	6138-6139	a	_	_	
32-24	6140-6146	direct	_	_	
32-25	6147-6158	interaction	_	_	
32-26	6159-6161	of	_	_	
32-27	6162-6165	the	_	_	
32-28	6166-6169	two	_	_	
32-29	6170-6180	components	_	_	
32-30	6180-6181	.	_	_	

#Text=For example, different cells such as effector cells and target cells can be connected via a bispecific antibody.
33-1	6182-6185	For	_	_	
33-2	6186-6193	example	_	_	
33-3	6193-6194	,	_	_	
33-4	6195-6204	different	_	_	
33-5	6205-6210	cells	_	_	
33-6	6211-6215	such	_	_	
33-7	6216-6218	as	_	_	
33-8	6219-6227	effector	_	_	
33-9	6228-6233	cells	_	_	
33-10	6234-6237	and	_	_	
33-11	6238-6244	target	_	_	
33-12	6245-6250	cells	_	_	
33-13	6251-6254	can	_	_	
33-14	6255-6257	be	_	_	
33-15	6258-6267	connected	_	_	
33-16	6268-6271	via	_	_	
33-17	6272-6273	a	_	_	
33-18	6274-6284	bispecific	_	_	
33-19	6285-6293	antibody	_	_	
33-20	6293-6294	.	_	_	

#Text=Encompassed, but not limited, by the present invention are antibodies or fragments thereof which bind, on the one hand, a soluble antigen as defined herein, and, on the other hand, an antigen or receptor on the surface of a tumor cell.
#Text=[0182] According to the invention, the nucleic acid of the inventive polymeric carrier cargo complex may also encode intrabodies, wherein these intrabodies may be antibodies as defined herein.
34-1	6295-6306	Encompassed	_	_	
34-2	6306-6307	,	_	_	
34-3	6308-6311	but	_	_	
34-4	6312-6315	not	_	_	
34-5	6316-6323	limited	_	_	
34-6	6323-6324	,	_	_	
34-7	6325-6327	by	_	_	
34-8	6328-6331	the	_	_	
34-9	6332-6339	present	_	_	
34-10	6340-6349	invention	_	_	
34-11	6350-6353	are	_	_	
34-12	6354-6364	antibodies	_	_	
34-13	6365-6367	or	_	_	
34-14	6368-6377	fragments	_	_	
34-15	6378-6385	thereof	_	_	
34-16	6386-6391	which	_	_	
34-17	6392-6396	bind	_	_	
34-18	6396-6397	,	_	_	
34-19	6398-6400	on	_	_	
34-20	6401-6404	the	_	_	
34-21	6405-6408	one	_	_	
34-22	6409-6413	hand	_	_	
34-23	6413-6414	,	_	_	
34-24	6415-6416	a	_	_	
34-25	6417-6424	soluble	_	_	
34-26	6425-6432	antigen	_	_	
34-27	6433-6435	as	_	_	
34-28	6436-6443	defined	_	_	
34-29	6444-6450	herein	_	_	
34-30	6450-6451	,	_	_	
34-31	6452-6455	and	_	_	
34-32	6455-6456	,	_	_	
34-33	6457-6459	on	_	_	
34-34	6460-6463	the	_	_	
34-35	6464-6469	other	_	_	
34-36	6470-6474	hand	_	_	
34-37	6474-6475	,	_	_	
34-38	6476-6478	an	_	_	
34-39	6479-6486	antigen	_	_	
34-40	6487-6489	or	_	_	
34-41	6490-6498	receptor	_	_	
34-42	6499-6501	on	_	_	
34-43	6502-6505	the	_	_	
34-44	6506-6513	surface	_	_	
34-45	6514-6516	of	_	_	
34-46	6517-6518	a	_	_	
34-47	6519-6524	tumor	_	_	
34-48	6525-6529	cell	_	_	
34-49	6529-6530	.	_	_	
34-50	6531-6532	[	_	_	
34-51	6532-6536	0182	_	_	
34-52	6536-6537	]	_	_	
34-53	6538-6547	According	_	_	
34-54	6548-6550	to	_	_	
34-55	6551-6554	the	_	_	
34-56	6555-6564	invention	_	_	
34-57	6564-6565	,	_	_	
34-58	6566-6569	the	_	_	
34-59	6570-6577	nucleic	_	_	
34-60	6578-6582	acid	_	_	
34-61	6583-6585	of	_	_	
34-62	6586-6589	the	_	_	
34-63	6590-6599	inventive	_	_	
34-64	6600-6609	polymeric	_	_	
34-65	6610-6617	carrier	_	_	
34-66	6618-6623	cargo	_	_	
34-67	6624-6631	complex	_	_	
34-68	6632-6635	may	_	_	
34-69	6636-6640	also	_	_	
34-70	6641-6647	encode	_	_	
34-71	6648-6659	intrabodies	_	_	
34-72	6659-6660	,	_	_	
34-73	6661-6668	wherein	_	_	
34-74	6669-6674	these	_	_	
34-75	6675-6686	intrabodies	_	_	
34-76	6687-6690	may	_	_	
34-77	6691-6693	be	_	_	
34-78	6694-6704	antibodies	_	_	
34-79	6705-6707	as	_	_	
34-80	6708-6715	defined	_	_	
34-81	6716-6722	herein	_	_	
34-82	6722-6723	.	_	_	

#Text=Since these antibodies are intracellular expressed antibodies, i.e. antibodies which may be encoded by nucleic acids localized in specific areas of the cell and also expressed there, such antibodies may be termed intrabodies.
35-1	6724-6729	Since	_	_	
35-2	6730-6735	these	_	_	
35-3	6736-6746	antibodies	_	_	
35-4	6747-6750	are	_	_	
35-5	6751-6764	intracellular	_	_	
35-6	6765-6774	expressed	_	_	
35-7	6775-6785	antibodies	_	_	
35-8	6785-6786	,	_	_	
35-9	6787-6790	i.e	_	_	
35-10	6790-6791	.	_	_	
35-11	6792-6802	antibodies	_	_	
35-12	6803-6808	which	_	_	
35-13	6809-6812	may	_	_	
35-14	6813-6815	be	_	_	
35-15	6816-6823	encoded	_	_	
35-16	6824-6826	by	_	_	
35-17	6827-6834	nucleic	_	_	
35-18	6835-6840	acids	_	_	
35-19	6841-6850	localized	_	_	
35-20	6851-6853	in	_	_	
35-21	6854-6862	specific	_	_	
35-22	6863-6868	areas	_	_	
35-23	6869-6871	of	_	_	
35-24	6872-6875	the	_	_	
35-25	6876-6880	cell	_	_	
35-26	6881-6884	and	_	_	
35-27	6885-6889	also	_	_	
35-28	6890-6899	expressed	_	_	
35-29	6900-6905	there	_	_	
35-30	6905-6906	,	_	_	
35-31	6907-6911	such	_	_	
35-32	6912-6922	antibodies	_	_	
35-33	6923-6926	may	_	_	
35-34	6927-6929	be	_	_	
35-35	6930-6936	termed	_	_	
35-36	6937-6948	intrabodies	_	_	
35-37	6948-6949	.	_	_	
